Table 3A) Primary End Points |
|
|
|
|
Primary End Points |
All (n = 403) |
RF (n =
345) |
Cryo (n = 58) |
p value |
AAR |
179 (44.4) |
151 (43.8) |
28 (48.3) |
p = 0.52 |
Antiarrhythmic use |
55 (13.6) |
45 (13.0) |
10 (17.2) |
p =
0.51 |
Repeat ablation |
73 (18.1) |
65 (18.8) |
8 (13.8) |
p =
0.46 |
Cardioversion |
75 (18.6) |
63 (18.3) |
12 (20.7) |
p =
0.80 |
Table 3B) |
|
|
|
|
AAR by Utah Stage |
|
|
|
|
Utah Stage 1+2 |
All (n = 232) |
RF (n = 200) |
Cryo (n = 32) |
p value |
AAR |
103 (44.4) |
88 (44.0) |
15 (46.9) |
p = 0.91 |
Utah Stage 3+4 |
All (n = 171) |
RF (n = 145) |
Cryo (n = 26) |
p value |
AAR |
76 (44.4) |
63 (43.4) |
13 (50.0) |
p = 0.69 |